Ann: ACTION3 IND Approved in China, page-98

if you’re going to throw accusations around then please get your facts right. It’s a 6 week (not 6 month) stabilisation. (See American Congress abstract link I previously posted).
> some of the 133 will have failed screening process and be rejected patients , they don’t count for trial
> treverea sparsentan trial in Fgs screened 724 patients to end up with 371 meaning almost 50% screen fail (see published paper available on line)
> only the randomised number matters for trial timelines as with any trial. There must be an update on numbers at some stage , biotechs always update market on this don’t they? so we’ll all know soon enough what progress has been since July 2023 ANN said 72nd patient randomised. By your logic that number should be well over 100 randomise into the trial by now , let’s see.